Top-Rated StocksTop-RatedNASDAQ:TRVI Trevi Therapeutics (TRVI) Stock Price, News & Analysis $14.50 0.00 (0.00%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$14.59 +0.09 (+0.61%) As of 09:15 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Trevi Therapeutics Stock (NASDAQ:TRVI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Trevi Therapeutics alerts:Sign Up Key Stats Today's Range$14.39▼$15.3550-Day Range$10.61▼$15.4052-Week Range$5.38▼$16.12Volume1.99 million shsAverage Volume1.94 million shsMarket Capitalization$2.06 billionP/E RatioN/ADividend YieldN/APrice Target$22.90Consensus RatingBuy Company Overview Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions. Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy. In addition to its TTX program, Trevi maintains a pipeline of preclinical and discovery-stage assets aimed at broadening treatment options for patients with refractory pain syndromes. Headquartered in San Diego, California, Trevi Therapeutics conducts research and development activities at its U.S. facilities and collaborates with academic institutions and contract research organizations to advance its clinical candidates. The company’s leadership team combines expertise in pharmaceutical development, regulatory affairs and commercialization strategy to guide its growth as a specialty biopharmaceutical innovator.AI Generated. May Contain Errors. Read More Trevi Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks59th Percentile Overall ScoreTRVI MarketRank™: Trevi Therapeutics scored higher than 59% of companies evaluated by MarketBeat, and ranked 333rd out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingTrevi Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 9 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialTrevi Therapeutics has a consensus price target of $22.90, representing about 57.9% upside from its current price of $14.50.Amount of Analyst CoverageTrevi Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Trevi Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Trevi Therapeutics are expected to decrease in the coming year, from ($0.45) to ($0.56) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Trevi Therapeutics is -45.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Trevi Therapeutics is -45.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTrevi Therapeutics has a P/B Ratio of 10.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for TRVI. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTrevi Therapeutics does not currently pay a dividend.Dividend GrowthTrevi Therapeutics does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.27 News SentimentTrevi Therapeutics has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 28 news articles for Trevi Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 6 people have searched for TRVI on MarketBeat in the last 30 days. This is a decrease of -14% compared to the previous 30 days.MarketBeat Follows3 people have added Trevi Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Trevi Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders18.30% of the stock of Trevi Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions95.76% of the stock of Trevi Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Trevi Therapeutics' insider trading history. Receive TRVI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Trevi Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TRVI Stock News HeadlinesTrevi Therapeutics (TRVI) Gets a Buy from H.C. WainwrightMay 8 at 12:47 AM | theglobeandmail.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Q1 2026 Earnings Call TranscriptMay 7, 2026 | insidermonkey.comThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.May 11 at 1:00 AM | Banyan Hill Publishing (Ad)Trevi Therapeutics (NASDAQ:TRVI) Receives "Buy" Rating from HC WainwrightMay 7, 2026 | americanbankingnews.comWhy Trevi Therapeutics (TRVI) Is Up 5.9% After Extending Its Cash Runway Into 2030May 6, 2026 | finance.yahoo.comTrevi Therapeutics, Inc. (TRVI) Q1 2026 Earnings Call TranscriptMay 6, 2026 | seekingalpha.comTrevi Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdatesMay 5, 2026 | globenewswire.comTrevi Therapeutics Announces Oral Presentation and Multiple Posters Accepted at the American Thoracic Society (ATS) 2026 International ConferenceApril 30, 2026 | globenewswire.comSee More Headlines TRVI Stock Analysis - Frequently Asked Questions How have TRVI shares performed this year? Trevi Therapeutics' stock was trading at $12.52 at the beginning of 2026. Since then, TRVI stock has increased by 15.8% and is now trading at $14.50. How were Trevi Therapeutics' earnings last quarter? Trevi Therapeutics, Inc. (NASDAQ:TRVI) issued its quarterly earnings results on Tuesday, May, 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.07) by $0.02. Read the conference call transcript. When did Trevi Therapeutics IPO? Trevi Therapeutics (TRVI) raised $70 million in an initial public offering (IPO) on Tuesday, May 7th 2019. The company issued 4,700,000 shares at a price of $14.00-$16.00 per share. SVB Leerink, Stifel and BMO Capital Markets acted as the underwriters for the IPO and Needham & Company was co-manager. Who are Trevi Therapeutics' major shareholders? Top institutional investors of Trevi Therapeutics include Emerald Advisers LLC (1.43%), Pictet Asset Management Holding SA (1.33%), Emerald Mutual Fund Advisers Trust (0.98%) and Candriam S.C.A. (0.60%). Insiders that own company stock include David P Meeker, Thomas Sciascia, Jennifer L Good, Farrell Simon and Lisa Delfini. View institutional ownership trends. How do I buy shares of Trevi Therapeutics? Shares of TRVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Trevi Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Trevi Therapeutics investors own include JPMorgan Chase & Co. (JPM), Predictive Oncology (POAI), Ford Motor (F), Tesla (TSLA), Meta Platforms (META), Abbott Laboratories (ABT) and Bank of America (BAC). Company Calendar Last Earnings5/05/2026Today5/11/2026Bank of America Global Healthcare Conference 20265/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (27m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 TRVI's financial health is in the Green zone, according to TradeSmith. TRVI has been in this zone for over 27 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TRVI CIK1563880 Webwww.trevitherapeutics.com Phone(203) 304-2499FaxN/AEmployees20Year Founded2011Price Target and Rating Average Price Target for Trevi Therapeutics$22.90 High Price Target$30.00 Low Price Target$16.00 Potential Upside/Downside+57.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($0.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$42.76 million Net MarginsN/A Pretax MarginN/A Return on Equity-23.94% Return on Assets-22.76% Debt Debt-to-Equity RatioN/A Current Ratio19.66 Quick Ratio19.66 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.43 per share Price / Book10.14Miscellaneous Outstanding Shares141,980,000Free Float115,998,000Market Cap$2.06 billion OptionableOptionable Beta1.07 Social Links The 10 Best AI Stocks to Own in 2026Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:TRVI) was last updated on 5/11/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)A little-known stock pick with money-doubling potential over the next year is revealed for free in the first t...Paradigm Press | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredTrade this between 9:30 and 10:45 am ESTThe first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...Base Camp Trading | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredElon’s AI supercomputer just went live. Here’s my #1 stock.Is Elon about to trigger another 315X opportunity? Elon gave Tesla investors the chance to make more than 3...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Trevi Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Trevi Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TRVI Stock Alerts